Agenus (AGEN)

Executive Summary

Agenus is a clinical-stage biotechnology company developing next-generation immunotherapies, notably the Fc-enhanced anti-CTLA-4 antibody botensilimab in combination with the anti-PD-1 antibody balstilimab. The combination has shown promise in treating 'cold' tumors such as microsatellite-stable colorectal cancer (MSS CRC), where checkpoint inhibitors have historically failed. Beyond MSS CRC, the pipeline includes Phase 2 trials in pancreatic ductal adenocarcinoma, melanoma, and non-small cell lung cancer, with multiple active studies recruiting or ongoing. The company employs a hybrid strategy of advancing key assets internally while partnering others to fund development, which has helped extend its cash runway despite significant R&D expenses. Botensilimab's differentiated mechanism, leveraging Fc-mediated effector function, positions it as a potential best-in-class CTLA-4 inhibitor if clinical data continue to support its efficacy and safety profile.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 data for botensilimab + balstilimab in MSS colorectal cancer60% success
• Q1 2027Phase 2 data for botensilimab combination in pancreatic ductal adenocarcinoma (NCT05630183)40% success
• Q3 2026Potential partnership or licensing deal for botensilimab or balstilimab50% success